Antimicrobial agent triclosan, used in soaps and detergents, may cause cancer
the ONA take:
Triclosan, a popular antimicrobial agent in soaps, detergents, and plastics, has been found to promote liver cancer in mice after long-term exposure.
In this study, mice were fed chow consisting of 0.08% triclosan. The mice had enlarged livers and liver fibrosis after 8 months of exposure, which is equivalent to approximately 18 human years. Liver fibrosis has been shown to promote liver cancer in previous studies. Additional studies examined how triclosan affects liver tumor formation.
Those results indicated mice exposed to triclosan developed more tumors, and the tumors were larger compared with tumors found in mice not exposed to the agent. Triclosan is absorbed into the human body through the skin and the gastrointestinal tract. “We could reduce most human and environmental exposures by eliminating uses of triclosan that are high volume, but of low benefit, such as inclusion in liquid hand soaps,” said one of the study co-authors.
Triclosan is currently under review by the US FDA due to previous studies linking it to hormone disruption and impaired muscle contraction. Major consumer products manufacturers, such as Procter and Gamble and Unilever, are already eliminating the agent from their products.
Triclosan has been found to promote liver cancer in mice.
Long-term exposure to triclosan—a popular antimicrobial agent in soaps, detergents, and plastics, still in use in the Philippines—has been found to promote liver cancer in mice. The study was conducted by scientists from the University of California (San Diego and Davis) and the Salk Institute for Biological Studies and was published in the journal Proceedings of the National Academy of Sciences.
In this study, the researchers fed mice with chow consisting of 0.08% triclosan [5-chloro-2-(2, 4-dichlorophenoxy)phenol]. After eight months of exposure (roughly equivalent to 18 human years), the mice showed enlarged livers and liver fibrosis. Previous studies have shown that liver fibrosis, or the formation of excess fibrous connective tissue in the liver, promotes liver cancer.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Mammograms (Fact Sheet)
- Shifts in Cancer Burden for People With HIV Projected
- Tissue Biobank Procurement Consent Should Include Discussion of Confidentiality Risks
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|